Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Creutzig

Showing results (51-60 of 158) with videos related to

Pageof 16
Sort By:
Klinische Padiatrie|May 1, 1984
[Acute myelogenous leukemia in children under 2 years of age: studies and treatment results in 23 children in the AML therapy study BFM-78]U Creutzig, A Schaaff, J Ritter, et al.
Klinische Padiatrie|November 5, 2011
[Adolescents with cancer - administrative, clinical and scientific implications]U Göbel, U Creutzig, T Klingebiel, et al.
British Journal of Haematology|October 29, 2000
Primary myelosarcomas are associated with a high rate of relapse: report on 34 children from the acute myeloid leukaemia-Berlin-Frankfurt-Münster studiesD Reinhardt, A Pekrun, M Lakomek, et al.
Klinische Padiatrie|August 8, 2002
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]D Reinhardt, G Hempel, G Fleischhack, et al.
Leukemia|October 31, 2003
Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93T Lehrnbecher, D Varwig, J Kaiser, et al.
Haematology and Blood Transfusion|January 1, 1990
Prognostic significance of eosinophilia in acute myelomonocytic leukemia in relation to induction treatmentU Creutzig, G Niederbiermann, J Ritter, et al.
Studies in Health Technology and Informatics|June 29, 1999
Computer-aided documentation and therapy planning in pediatric oncologyT Wiedemann, P Knaup, A Bachert, et al.
Klinische Padiatrie|December 17, 2003
[Quality management within the competence network of paediatric oncology and haematology]U Creutzig, M Zimmermann, J Hannemann, et al.
Haematology and Blood Transfusion|January 1, 1987
Treatment results in childhood AML, with special reference to the German studies BFM-78 and BFM-83U Creutzig, J Ritter, M Budde, et al.
Leukemia|May 28, 2005
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensityU Creutzig, D Reinhardt, S Diekamp, et al.
Pageof 16

Showing results (51-60 of 158) with videos related to

Sort By:
Pageof 16
Klinische Padiatrie|May 1, 1984
[Acute myelogenous leukemia in children under 2 years of age: studies and treatment results in 23 children in the AML therapy study BFM-78]U Creutzig, A Schaaff, J Ritter, et al.
Klinische Padiatrie|November 5, 2011
[Adolescents with cancer - administrative, clinical and scientific implications]U Göbel, U Creutzig, T Klingebiel, et al.
British Journal of Haematology|October 29, 2000
Primary myelosarcomas are associated with a high rate of relapse: report on 34 children from the acute myeloid leukaemia-Berlin-Frankfurt-Münster studiesD Reinhardt, A Pekrun, M Lakomek, et al.
Klinische Padiatrie|August 8, 2002
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]D Reinhardt, G Hempel, G Fleischhack, et al.
Leukemia|October 31, 2003
Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93T Lehrnbecher, D Varwig, J Kaiser, et al.
Haematology and Blood Transfusion|January 1, 1990
Prognostic significance of eosinophilia in acute myelomonocytic leukemia in relation to induction treatmentU Creutzig, G Niederbiermann, J Ritter, et al.
Studies in Health Technology and Informatics|June 29, 1999
Computer-aided documentation and therapy planning in pediatric oncologyT Wiedemann, P Knaup, A Bachert, et al.
Klinische Padiatrie|December 17, 2003
[Quality management within the competence network of paediatric oncology and haematology]U Creutzig, M Zimmermann, J Hannemann, et al.
Haematology and Blood Transfusion|January 1, 1987
Treatment results in childhood AML, with special reference to the German studies BFM-78 and BFM-83U Creutzig, J Ritter, M Budde, et al.
Leukemia|May 28, 2005
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensityU Creutzig, D Reinhardt, S Diekamp, et al.
Pageof 16